Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and PK of Doravirine/Islatravir FDC
NCT06719570Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by Merck & Co. Primary endpoints: Area under the curve from time 0-infinity of Doravirine, Area under the curve from time 0 to last measurable concentration of Doravirine and 5 more. Started Jan 2024; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06719570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719570.